New Study Demonstrating the Selectivity of Progenra's Novel Anti-Tumor Compound.
Senior author Benedikt Kessler noted that the studies were made possible by Progenra's collection of highly selective and non-selective DUB inhibitor tool compounds. Mikael Altun, the lead author, stated that combining DUB active site probes with proteomics affords researchers, for the first time, the ability to generate DUB inhibition profiles and measure changes in the content of the substrates of DUBs in living cells - a key translational step in the development of new drugs for the treatment of cancer, pathogen infection and neurodegenerative disorders.
The DUB USP7 is a well validated target for the treatment of neoplastic disease. USP7 stabilizes oncogenic proteins and promotes the degradation of tumor suppressors such as p53. Due to its broad range of oncogenic protein substrates, USP7 inhibition is predicted to be efficacious for the treatment of both p53 wild type and p53 mutant tumors.
About University of Oxford
The University of Oxford (www.ox.ac.uk), founded in the 12th century, was the first University in the English-speaking world and is at the forefront of centers of learning, teaching and research. Oxford is one of the world's most influential and international universities and attracts students from 140 countries.
About Progenra, Inc.
Founded in 2002, Progenra (www.progenra.com) seeks to discover and develop high value medicines exploiting ubiquitin pathways. Utilizing its world-class UbiPro[TM] Drug Discovery Platform, Progenra identifies novel modulators of ubiquitin targets as potential drugs exploiting the roles of ubiquitin in disease.
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 28, 2011|
|Previous Article:||WWF Recognises Oriflame's Commitment to Sustainable Palm Oil.|
|Next Article:||Taiwan's First International Surfing Competition Held in Taitung.|